Skip to main content
OKYO Pharma Ltd logo

OKYO Pharma Ltd — Investor Relations & Filings

Ticker · OKYO ISIN · US6793451088 US Manufacturing
Open in API
Filings indexed 274 across all filing types
Latest filing 2019-05-20 Declaration of Voting R…
Country US United States of America
Listing US OKYO

About OKYO Pharma Ltd

https://okyopharma.com/

OKYO Pharma Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for inflammatory eye diseases and chronic pain. The company's primary focus is on addressing significant unmet medical needs in neuropathic corneal pain (NCP) and dry eye disease (DED). Its lead product candidate, Urcosimod (OK-101), is a novel G protein-coupled receptor (GPCR) agonist that targets the chemerin receptor to produce anti-inflammatory and pain-reducing effects. OKYO is the first company to receive Investigational New Drug (IND) clearance from the FDA to clinically evaluate a drug specifically for NCP, a condition with no approved treatments. Urcosimod has also been granted Fast Track Designation by the FDA for the treatment of NCP.

Recent filings

Filing Released Lang Actions
Result of General Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement from OKYO Pharma Limited regarding the results of a General Meeting, including a detailed table of voting results (For, Against, Withheld). It also covers the admission of new subscription shares and the resulting total voting rights. Because the primary purpose is to report the outcome of shareholder voting at a meeting, it falls under the Declaration of Voting Results & Voting Rights Announcements category.
2019-05-20 English
OKYO Circular
Capital/Financing Update Classification · 95% confidence The document is a detailed notice regarding the subscription of new ordinary shares, the proposed waiver under Rule 9 of the Takeover Code, and a notice of a General Meeting. It includes a timetable for the General Meeting, subscription statistics, and instructions for shareholders on voting and proxy submission. The content focuses on capital raising through a share subscription and related shareholder meeting matters. There is no indication of it being an annual report, earnings release, or audit report. It is not a transcript or remuneration report. The document is not a simple announcement but a full notice with detailed information about the subscription and meeting. This fits the category of Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through the subscription of new shares and related shareholder approvals.
2019-05-01 English
Subscription and Waiver
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from OKYO Pharma Limited regarding a capital raise (subscription of new shares) and a notice of a General Meeting to approve a waiver under the Takeover Code. While it contains details about the subscription, it explicitly states that a 'Circular' is being posted to shareholders and provides a timetable for the upcoming General Meeting. According to the 'Menu vs Meal' rule, this document serves as an announcement of the transaction and the upcoming meeting rather than the full proxy statement or the final report itself. Therefore, it is classified as a Report Publication Announcement (RPA) as it announces the publication of the Circular and the General Meeting details.
2019-04-26 English
Presentation of Preclinical Data
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from the London Stock Exchange regarding OKYO Pharma Limited. It details the presentation of preclinical data for a specific drug candidate (OKYO-0101) at a scientific conference. Since it is a general regulatory announcement regarding company research and development progress that does not fit into specific categories like financial reports, dividends, or M&A, it is classified as a Regulatory Filing (RNS).
2019-03-07 English
Corporate Update
Regulatory Filings Classification · 98% confidence The document is a corporate update issued via the London Stock Exchange's RNS (Regulatory News Service). It provides a progress report on the company's R&D programs, specifically regarding Chemerin and BAM8 assets, and outlines future development timelines. As it is a general regulatory announcement regarding company operations and strategy that does not fit into specific categories like financial reports, dividends, or M&A, it is classified as a Regulatory Filing (RNS).
2019-01-23 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim results for the six months to 30 September 2018' and contains comprehensive unaudited consolidated interim financial statements, including the statement of comprehensive income and statement of financial position. It is not merely an announcement of a report, but the report itself, containing substantive financial data for a period shorter than a full fiscal year. Therefore, it is classified as an Interim / Quarterly Report. H1 2018
2018-11-30 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.